Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is rapidly expanding in the diagnostic pathway of prostate cancer (PCa). 68Ga-PSMA PET/CT, the most studied PSMA radiotracer, is currently recommended in case of biochemical recurrence after radical prostatectomy [1]. It is also being progressively used before surgery [2] for primary staging of highrisk prostate cancer, particularly when conventional imaging is negative with high clinical suspicion of metastatic disease.
Prebiopsy 68Ga-PSMA PET imaging. can we improve the current diagnostic pathway for prostate cancer? / Albisinni, Simone; Sarkis, Julien; Diamand, Romain; De Nunzio, Cosimo. - In: PROSTATE CANCER AND PROSTATIC DISEASES. - ISSN 1365-7852. - 26:1(2022), pp. 1-3. [10.1038/s41391-022-00593-8]
Prebiopsy 68Ga-PSMA PET imaging. can we improve the current diagnostic pathway for prostate cancer?
Albisinni, Simone
;De Nunzio, Cosimo
2022
Abstract
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is rapidly expanding in the diagnostic pathway of prostate cancer (PCa). 68Ga-PSMA PET/CT, the most studied PSMA radiotracer, is currently recommended in case of biochemical recurrence after radical prostatectomy [1]. It is also being progressively used before surgery [2] for primary staging of highrisk prostate cancer, particularly when conventional imaging is negative with high clinical suspicion of metastatic disease.| File | Dimensione | Formato | |
|---|---|---|---|
|
Albisinni_Prebiopsy-68Ga-PSMA-PET-imaging_2022.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
306.21 kB
Formato
Adobe PDF
|
306.21 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
